Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-28 18:00 |
Nicox : Rapport Annuel 2022
|
French | 162.1 KB | ||
| 2023-04-28 07:30 |
Procédure d'examen prioritaire de la demande d’autorisation de mise sur le marc…
|
French | 83.8 KB | ||
| 2023-04-28 07:30 |
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZER…
|
English | 72.7 KB | ||
| 2023-04-26 09:57 |
Franchissement de seuils
|
French | 336.2 KB | ||
| 2023-04-26 09:00 |
Nicox : Transfert des titres de la Société Nicox sur le marché Euronext Growth …
|
French | 124.9 KB | ||
| 2023-04-26 09:00 |
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023
|
English | 124.2 KB | ||
| 2023-04-26 07:30 |
Nouvelles données sur deux composés de Nicox, NCX 470 et NCX 1728, présentées à…
|
French | 78.4 KB | ||
| 2023-04-26 07:30 |
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
|
English | 75.8 KB | ||
| 2023-04-24 17:45 |
Number of voting rigts as of April 24, 2023
|
English | 119.5 KB | ||
| 2023-04-24 17:45 |
Nombre de droits de vote au 24 avril 2023
|
French | 119.0 KB | ||
| 2023-04-24 07:30 |
Nicox : Assemblée Générale Ordinaire 2023 le 1er juin 2023
|
French | 165.0 KB | ||
| 2023-04-24 07:30 |
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
|
English | 164.7 KB | ||
| 2023-04-19 07:30 |
Nicox Provides First Quarter 2023 Financial and Business Highlights
|
English | 224.3 KB | ||
| 2023-04-19 07:30 |
Nicox : Résumé financier et point d’activité du premier trimestre 2023
|
French | 222.5 KB | ||
| 2023-04-14 07:30 |
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug…
|
English | 80.0 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
